<DOC>
	<DOC>NCT00192504</DOC>
	<brief_summary>MEDI-524 administered as a single IV dose at 3, 15, and 30 mg/kg to children hospitalized with RSV infection was safe and well tolerated.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>All male or female children must have met all of the following criteria: Previously healthy Age £24 months at the time of randomization Gestational age ³36 weeks gestation Randomization within 24 hours after hospitalization Hospitalized for lower respiratory tract illness (i.e. RSV bronchiolitis and/or pneumonia) documented by positive RSV antigen detection or culture in respiratory secretions within 72 hours before randomization Patients who met any of the following criteria were not eligible for entry into the study: Already received or would receive ribavirin or other antiviral treatment for the current episode of RSV infection prior to randomization Required intubation for ventilatory support Any medically significant underlying ongoing chronic illness or organ system dysfunction or other known acute illness, other than RSV infection Known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or other neurologic disorder or immunodeficiency Requirement for supplemental oxygen at any time prior to the current RSV infection (brief use of oxygen in the immediate postnatal period to treat a transient condition was allowed) Mechanical ventilation at any time prior to the onset of the current RSV infection Congenital heart disease (children with medically or surgically corrected patent ductus arteriosus [PDA], small atrial septal defect [ASD] or ventricular septal defect [VSD] were allowed) Previous reaction to IVIG, blood products, or other foreign proteins Prior use of IVIG, RSVIGIV (RespiGamÒ), palivizumab (SynagisÒ), or other immunoglobulin products within the past 2 months Currently receiving other investigational agents or have received any other investigational agents within the last 3 months Prior or current participation in any investigational study with a therapeutic agent or vaccine for RSV</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>